Meta-analysis: combination of meropenem vs ceftazidime and amikacin for empirical treatment of cancer patients with febrile neutropenia

BACKGROUND: Meropenem monotherapy vs ceftazidime plus amikacin have been approved for use against febrile neutropenia. To assess the effectiveness and safety of them for empirical treatment of cancer patients with febrile neutropenia, we conducted a meta-analysis of randomized controlled trial. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying, Du, Zhichao, Chen, Yongdong, Liu, Yugang, Yang, Zhitang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909104/
https://www.ncbi.nlm.nih.gov/pubmed/33663117
http://dx.doi.org/10.1097/MD.0000000000024883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909104/
https://www.ncbi.nlm.nih.gov/pubmed/33663117
http://dx.doi.org/10.1097/MD.0000000000024883

Ejemplares similares